$RCUS News

Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts

Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22

Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report

Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34

Arcus Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences (NYSE:RCUS) Q1 Loss Narrows But Revenues Miss Estimates; Focus Shifts to Kidney Cancer Drug Casdatifan

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate

Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences shares are trading lower after the company announced that it discontinued its phase 3 STAR-121 trial due to futility.